These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 36881979)
1. COVID-19 and beyond: Reassessing the role of thymosin alpha1 in lung infections. Bellet MM; Renga G; Pariano M; Stincardini C; D'Onofrio F; Goldstein AL; Garaci E; Romani L; Costantini C Int Immunopharmacol; 2023 Apr; 117():109949. PubMed ID: 36881979 [TBL] [Abstract][Full Text] [Related]
2. Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era. Mao L Int Immunopharmacol; 2023 Apr; 117():109952. PubMed ID: 36871535 [TBL] [Abstract][Full Text] [Related]
3. Thymosin α1 modulated the immune landscape of COVID-19 patients revealed by single-cell RNA and TCR sequencing. Bai H; Liang L; Qi X; Xu Y; Liu Y; Ren D; Cai Z; Mao W; Wang X; Qin H; Hu F; Shi B Int Immunopharmacol; 2023 Nov; 124(Pt B):110983. PubMed ID: 37769533 [TBL] [Abstract][Full Text] [Related]
4. Thymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection. Minutolo A; Petrone V; Fanelli M; Maracchioni C; Giudice M; Teti E; Coppola L; Sorace C; Iannetta M; Tony Miele M; Bernardini S; Mastino A; Sinibaldi Vallebona P; Balestrieri E; Andreoni M; Sarmati L; Grelli S; Garaci E; Matteucci C Int Immunopharmacol; 2023 May; 118():110055. PubMed ID: 36989892 [TBL] [Abstract][Full Text] [Related]
5. Novel evidence of Thymosin α1 immunomodulatory properties in SARS-CoV-2 infection: Effect on innate inflammatory response in a peripheral blood mononuclear cell-based in vitro model. Ricci D; Etna MP; Severa M; Fiore S; Rizzo F; Iannetta M; Andreoni M; Balducci S; Stefanelli P; Palamara AT; Coccia EM Int Immunopharmacol; 2023 Apr; 117():109996. PubMed ID: 36933449 [TBL] [Abstract][Full Text] [Related]
6. Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application. Tao N; Xu X; Ying Y; Hu S; Sun Q; Lv G; Gao J Molecules; 2023 Apr; 28(8):. PubMed ID: 37110771 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials. Dinetz E; Lee E Altern Ther Health Med; 2024 Jan; 30(1):6-12. PubMed ID: 38308608 [TBL] [Abstract][Full Text] [Related]
8. Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study. Wu M; Ji JJ; Zhong L; Shao ZY; Xie QF; Liu ZY; Wang CL; Su L; Feng YW; Liu ZF; Yao YM Int Immunopharmacol; 2020 Nov; 88():106873. PubMed ID: 32795897 [TBL] [Abstract][Full Text] [Related]
9. Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients. Wang Z; Chen J; Zhu C; Liu L; Qi T; Shen Y; Zhang Y; Xu L; Li T; Qian Z; Steinhart CR; Lu H Front Immunol; 2021; 12():568789. PubMed ID: 34149679 [TBL] [Abstract][Full Text] [Related]
10. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Romani L; Bistoni F; Perruccio K; Montagnoli C; Gaziano R; Bozza S; Bonifazi P; Bistoni G; Rasi G; Velardi A; Fallarino F; Garaci E; Puccetti P Blood; 2006 Oct; 108(7):2265-74. PubMed ID: 16741252 [TBL] [Abstract][Full Text] [Related]
11. Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes. Shang W; Zhang B; Ren Y; Wang W; Zhou D; Li Y Int Immunopharmacol; 2023 Jan; 114():109584. PubMed ID: 36527881 [TBL] [Abstract][Full Text] [Related]
12. A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection. Shehadeh F; Benitez G; Mylona EK; Tran QL; Tsikala-Vafea M; Atalla E; Kaczynski M; Mylonakis E J Infect Dis; 2023 Jan; 227(2):226-235. PubMed ID: 36056913 [TBL] [Abstract][Full Text] [Related]
13. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Liu Y; Pan Y; Hu Z; Wu M; Wang C; Feng Z; Mao C; Tan Y; Liu Y; Chen L; Li M; Wang G; Yuan Z; Diao B; Wu Y; Chen Y Clin Infect Dis; 2020 Nov; 71(16):2150-2157. PubMed ID: 32442287 [TBL] [Abstract][Full Text] [Related]
14. Thymalfasin for the treatment of chronic hepatitis B. Chien RN; Liaw YF Expert Rev Anti Infect Ther; 2004 Feb; 2(1):9-16. PubMed ID: 15482167 [TBL] [Abstract][Full Text] [Related]
17. Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients. Jia Z; Feng Z; Tian R; Wang Q; Wang L Immunopharmacol Immunotoxicol; 2015; 37(4):388-92. PubMed ID: 26250523 [TBL] [Abstract][Full Text] [Related]
18. Thymosin α1 protects from CTLA-4 intestinal immunopathology. Renga G; Bellet MM; Pariano M; Gargaro M; Stincardini C; D'Onofrio F; Mosci P; Brancorsini S; Bartoli A; Goldstein AL; Garaci E; Romani L; Costantini C Life Sci Alliance; 2020 Oct; 3(10):. PubMed ID: 32817121 [TBL] [Abstract][Full Text] [Related]